Literature DB >> 16334487

Expression of cyclins D1, D2, and D3 and Ki-67 in Leukemia.

Polák Jaroslav1, Hradcová Martina, Schwarz Jirí, Klamová Hana, Stöckbauer Petr, Kozák Tomás, Müller Julius, Haskovec Cedrik.   

Abstract

Cyclins are very important components of the cell cycle machinery because their levels regulate cell proliferation. They have also been found to be prognostic factors in various cancers. We studied the expression of the positive cell cycle regulators (D cyclins) and the cell proliferation marker (Ki-67) in human acute myeloid (AML), chronic myeloid (CML), acute lymphoblastic (ALL) and chronic lymphocytic (CLL) leukemia [mainly by comparative reverse transcription polymerase chain reaction (RT-PCR)]. Both leukemic and normal cells were positive for cyclin D3 expression. Significant differences were found in the expression of cyclin D1, which was the highest in leukocytes (CD19 + ) of CLL patients whereas lower expression was found in CML, AML and ALL patients and normal bone marrow and peripheral blood leukocytes (P < 0.001). The higher expression of cyclin D1 in leukocytes of CLL patients compared to CML patients was confirmed by quantitative real-time RT-PCR with a TaqMan probe in a subset of CLL and CML patients. Differences in cyclin D1 expression between CLL and CML patients were also confirmed on protein levels by western blotting. Expression of the proliferative marker Ki-67 was high in CML, ALL and AML cells and low in CD19-positive CLL cells. The results demonstrate that the level of cyclin D1 negatively correlates with the proliferation properties of leukemic cells. We did not find any significant relationship between cyclin D1 expression in cells of CML and AML patients and their clinical outcome.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16334487     DOI: 10.1080/10428190500215100

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  6 in total

1.  CD38 expression labels an activated subset within chronic lymphocytic leukemia clones enriched in proliferating B cells.

Authors:  Rajendra N Damle; Sonal Temburni; Carlo Calissano; Sophia Yancopoulos; Taraneh Banapour; Cristina Sison; Steven L Allen; Kanti R Rai; Nicholas Chiorazzi
Journal:  Blood       Date:  2007-08-07       Impact factor: 22.113

2.  Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.Na.

Authors:  Matthew J Olnes; Aarthie Shenoy; Barbara Weinstein; Loretta Pfannes; Kelsey Loeliger; Zachary Tucker; Xin Tian; Minjung Kwak; Francois Wilhelm; Agnes S M Yong; Irina Maric; Manoj Maniar; Phillip Scheinberg; Jerome Groopman; Neal S Young; Elaine M Sloand
Journal:  Leuk Res       Date:  2012-04-21       Impact factor: 3.156

3.  Sex hormone regulation of survivin gene expression.

Authors:  Nancy H Nabilsi; Russell R Broaddus; Adrienne S McCampbell; Karen H Lu; Henry T Lynch; Lee-May Chen; David S Loose
Journal:  J Endocrinol       Date:  2010-08-26       Impact factor: 4.286

4.  miR-15b/16-2 deletion promotes B-cell malignancies.

Authors:  Francesca Lovat; Matteo Fassan; Pierluigi Gasparini; Lara Rizzotto; Luciano Cascione; Marco Pizzi; Caterina Vicentini; Veronica Balatti; Dario Palmieri; Stefan Costinean; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2015-08-31       Impact factor: 11.205

5.  Bone marrow cell cycle markers in inherited bone marrow failure syndromes.

Authors:  Mohamad M Al-Rahawan; Blanche P Alter; Barbara J Bryant; M Tarek Elghetany
Journal:  Leuk Res       Date:  2008-07-07       Impact factor: 3.156

6.  Expression of P-glycoprotein, Cyclin D1 and Ki-67 in Acute Lymphoblastic Leukemia: Relation with Induction Chemotherapy and Overall Survival.

Authors:  Ghada M Elsayed; Manar M Ismail; Manar M Moneer
Journal:  Indian J Hematol Blood Transfus       Date:  2011-06-21       Impact factor: 0.900

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.